{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T02:25:18Z","timestamp":1767147918341,"version":"build-2238731810"},"reference-count":46,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,17]],"date-time":"2025-02-17T00:00:00Z","timestamp":1739750400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P01 CA 066996"],"award-info":[{"award-number":["P01 CA 066996"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["05\/01\/2020-4\/30\/2025"],"award-info":[{"award-number":["05\/01\/2020-4\/30\/2025"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceutical Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Oncology"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.omton.2025.200952","type":"journal-article","created":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T03:39:09Z","timestamp":1740022749000},"page":"200952","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Dual CARM1-and IKZF3-targeting: A novel approach to multiple myeloma therapy"],"prefix":"10.1016","volume":"33","author":[{"given":"Wei","family":"Ni","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Swati","family":"Garg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Basudev","family":"Chowdhury","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Sattler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dana","family":"Sanchez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chengcheng","family":"Meng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taisei","family":"Akatsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katherine A.","family":"Donovan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Qi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle Y.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cara Ann","family":"Starnbach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoxi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Tarazona","family":"Guzman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei Pin","family":"Teh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Stone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James D.","family":"Griffin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Buhrlage","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5679-9531","authenticated-orcid":false,"given":"Ellen","family":"Weisberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.omton.2025.200952_bib1","first-page":"391","article-title":"Multiple myeloma and diagnostic imaging","volume":"85","author":"Reisenbuckler","year":"2014","journal-title":"Radiol. Technol."},{"key":"10.1016\/j.omton.2025.200952_bib2","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1053\/j.seminoncol.2016.11.004","article-title":"Multiple myeloma epidemiology and survival: A unique malignancy","volume":"43","author":"Kazandjian","year":"2016","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.omton.2025.200952_bib3","first-page":"1184","article-title":"CAR T-Cell Therapy for Multiple Myeloma: A Clinical Practice-Oriented Review","volume":"114","author":"Sadek","year":"2023","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.omton.2025.200952_bib4","doi-asserted-by":"crossref","DOI":"10.3390\/antib8020034","article-title":"Investigational Monoclonal Antibodies in the Treatment of Multiple Myeloma: A Systematic Review of Agents under Clinical Development","volume":"8","author":"Iftikhar","year":"2019","journal-title":"Antibodies"},{"key":"10.1016\/j.omton.2025.200952_bib5","doi-asserted-by":"crossref","first-page":"2174","DOI":"10.1126\/science.284.5423.2174","article-title":"Regulation of transcription by a protein methyltransferase","volume":"284","author":"Chen","year":"1999","journal-title":"Science"},{"key":"10.1016\/j.omton.2025.200952_bib6","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms15571","article-title":"Global mapping of CARM1 substrates defines enzyme specificity and substrate recognition","volume":"8","author":"Shishkova","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omton.2025.200952_bib7","doi-asserted-by":"crossref","first-page":"7457","DOI":"10.1007\/s11033-023-08645-5","article-title":"Inhibition of CARM1 suppresses proliferation of multiple myeloma cells through activation of p53 signaling pathway","volume":"50","author":"Yang","year":"2023","journal-title":"Mol. Biol. Rep."},{"key":"10.1016\/j.omton.2025.200952_bib8","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-18446-z","article-title":"Identification of a CARM1 Inhibitor with Potent In\u00a0Vitro and In\u00a0Vivo Activity in Preclinical Models of Multiple Myeloma","volume":"7","author":"Drew","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.omton.2025.200952_bib9","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.83951","article-title":"Carm1-arginine methylation of the transcription factor C\/EBPalpha regulates transdifferentiation velocity","volume":"12","author":"Torcal Garcia","year":"2023","journal-title":"Elife"},{"key":"10.1016\/j.omton.2025.200952_bib10","doi-asserted-by":"crossref","first-page":"4050","DOI":"10.1182\/blood-2005-07-2817","article-title":"Combination therapy with lenalidomide plus dexamethasone (Rev\/Dex) for newly diagnosed myeloma","volume":"106","author":"Rajkumar","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.omton.2025.200952_bib11","doi-asserted-by":"crossref","DOI":"10.1177\/20406207221090089","article-title":"Pomalidomide- and dexamethasone-based regimens in the treatment of refractory\/relapsed multiple myeloma","volume":"13","author":"Fotiou","year":"2022","journal-title":"Ther. Adv. Hematol."},{"key":"10.1016\/j.omton.2025.200952_bib12","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1126\/science.1244851","article-title":"Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells","volume":"343","author":"Kronke","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.omton.2025.200952_bib13","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1126\/science.1177319","article-title":"Identification of a primary target of thalidomide teratogenicity","volume":"327","author":"Ito","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.omton.2025.200952_bib14","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1177\/205873920601900107","article-title":"c-MYC deregulation is involved in melphalan resistance of multiple myeloma: role of PDGF-BB","volume":"19","author":"Greco","year":"2006","journal-title":"Int. J. Immunopathol. Pharmacol."},{"key":"10.1016\/j.omton.2025.200952_bib15","doi-asserted-by":"crossref","first-page":"e368","DOI":"10.3324\/haematol.2017.186601","article-title":"Cereblon loss and up-regulation of c-Myc are associated with lenalidomide resistance in multiple myeloma patients","volume":"103","author":"Franssen","year":"2018","journal-title":"Haematologica"},{"key":"10.1016\/j.omton.2025.200952_bib16","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1182\/blood-2016-02-698092","article-title":"Targeted sequencing of refractory myeloma reveals a high incidence of mutations in CRBN and Ras pathway genes","volume":"128","author":"Kortum","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.omton.2025.200952_bib17","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1182\/blood.2020007081","article-title":"Multiple cereblon genetic changes are associated with acquired resistance to lenalidomide or pomalidomide in multiple myeloma","volume":"137","author":"Gooding","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.omton.2025.200952_bib18","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1186\/s13045-018-0666-5","article-title":"Growth factor independence 1 expression in myeloma cells enhances their growth, survival, and osteoclastogenesis","volume":"11","author":"Petrusca","year":"2018","journal-title":"J.\u00a0Hematol. Oncol."},{"key":"10.1016\/j.omton.2025.200952_bib19","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1158\/1535-7163.MCT-12-0135","article-title":"Drug resistance to inhibitors of the human double minute-2 E3 ligase is mediated by point mutations of p53, but can be overcome with the p53 targeting agent RITA","volume":"11","author":"Jones","year":"2012","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.omton.2025.200952_bib20","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/nature07064","article-title":"IRF4 addiction in multiple myeloma","volume":"454","author":"Shaffer","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.omton.2025.200952_bib21","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms15398","article-title":"pSILAC mass spectrometry reveals ZFP91 as IMiD-dependent substrate of the CRL4(CRBN) ubiquitin ligase","volume":"8","author":"An","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omton.2025.200952_bib22","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1182\/blood.2021014701","article-title":"Overcoming IMiD resistance in T-cell lymphomas through potent degradation of ZFP91 and IKZF1","volume":"139","author":"Wu","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.omton.2025.200952_bib23","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1111\/j.1582-4934.2008.00345.x","article-title":"Frabin and other related Cdc42-specific guanine nucleotide exchange factors couple the actin cytoskeleton with the plasma membrane","volume":"12","author":"Nakanishi","year":"2008","journal-title":"J.\u00a0Cell Mol. Med."},{"key":"10.1016\/j.omton.2025.200952_bib24","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nature18611","article-title":"A novel cereblon modulator recruits GSPT1 to the CRL4(CRBN) ubiquitin ligase","volume":"535","author":"Matyskiela","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.omton.2025.200952_bib25","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16071319","article-title":"Synergy between BRD9- and IKZF3-Targeting as a Therapeutic Strategy for Multiple Myeloma","volume":"16","author":"Chowdhury","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.omton.2025.200952_bib26","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/s41408-019-0173-0","article-title":"Identification of lenalidomide resistance pathways in myeloma and targeted resensitization using cereblon replacement, inhibition of STAT3 or targeting of IRF4","volume":"9","author":"Zhu","year":"2019","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.omton.2025.200952_bib27","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22031103","article-title":"Role of Aiolos and Ikaros in the Antitumor and Immunomodulatory Activity of IMiDs in Multiple Myeloma: Better to Lose Than to Find Them","volume":"22","author":"Cippitelli","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.omton.2025.200952_bib28","doi-asserted-by":"crossref","first-page":"18480","DOI":"10.18632\/oncotarget.24883","article-title":"TP-064, a potent and selective small molecule inhibitor of PRMT4 for multiple myeloma","volume":"9","author":"Nakayama","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.omton.2025.200952_bib29","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/nbt.3834","article-title":"Synergistic drug combinations for cancer identified in a CRISPR screen for pairwise genetic interactions","volume":"35","author":"Han","year":"2017","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.omton.2025.200952_bib30","doi-asserted-by":"crossref","first-page":"3269","DOI":"10.1038\/s41375-020-0908-8","article-title":"CARM1 inhibition reduces histone acetyltransferase activity causing synthetic lethality in CREBBP\/EP300-mutated lymphomas","volume":"34","author":"Veazey","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.omton.2025.200952_bib31","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1186\/s12964-024-01623-9","article-title":"Targeting Wnt\/beta-catenin signaling and its interplay with TGF-beta and Notch signaling pathways for the treatment of chronic wounds","volume":"22","author":"Gumede","year":"2024","journal-title":"Cell Commun. Signal."},{"key":"10.1016\/j.omton.2025.200952_bib32","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s43556-024-00188-w","article-title":"Multiple myeloma: signaling pathways and targeted therapy","volume":"5","author":"Lu","year":"2024","journal-title":"Mol. Biomed."},{"key":"10.1016\/j.omton.2025.200952_bib33","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1007\/s12094-017-1751-x","article-title":"Expression differences of genes in the PI3K\/AKT, WNT\/b-catenin, SHH, NOTCH and MAPK signaling pathways in CD34+ hematopoietic cells obtained from chronic phase patients with chronic myeloid leukemia and from healthy controls","volume":"20","author":"de Cassia Viu Carrara","year":"2018","journal-title":"Clin. Transl. Oncol."},{"key":"10.1016\/j.omton.2025.200952_bib34","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1038\/nchembio.2115","article-title":"Sensitivity and engineered resistance of myeloid leukemia cells to BRD9 inhibition","volume":"12","author":"Hohmann","year":"2016","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.omton.2025.200952_bib35","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/s41408-022-00704-7","article-title":"BRD9 degraders as chemosensitizers in acute leukemia and multiple myeloma","volume":"12","author":"Weisberg","year":"2022","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.omton.2025.200952_bib36","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ccr.2013.12.017","article-title":"CARMA: CARM1 methylation of SWI\/SNF in breast cancer","volume":"25","author":"Wang","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.omton.2025.200952_bib37","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ccr.2013.12.007","article-title":"CARM1 methylates chromatin remodeling factor BAF155 to enhance tumor progression and metastasis","volume":"25","author":"Wang","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.omton.2025.200952_bib38","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1158\/2643-3230.BCD-23-0061","article-title":"ETV4-Dependent Transcriptional Plasticity Maintains MYC Expression and Results in IMiD Resistance in Multiple Myeloma","volume":"5","author":"Neri","year":"2024","journal-title":"Blood Cancer Discov."},{"key":"10.1016\/j.omton.2025.200952_bib39","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1182\/blood-2018-03-840132","article-title":"Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma","volume":"132","author":"Walker","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.omton.2025.200952_bib40","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/s41408-022-00610-y","article-title":"Clonal and subclonal TP53 molecular impairment is associated with prognosis and progression in multiple myeloma","volume":"12","author":"Martello","year":"2022","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.omton.2025.200952_bib41","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2017.76","article-title":"Prevalence and timing of TP53 mutations in del(17p) myeloma and effect on survival","volume":"7","author":"Chin","year":"2017","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.omton.2025.200952_bib42","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/s41375-018-0196-8","article-title":"A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis","volume":"33","author":"Walker","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.omton.2025.200952_bib43","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0065-2571(84)90007-4","article-title":"Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors","volume":"22","author":"Chou","year":"1984","journal-title":"Adv. Enzym. Regul."},{"key":"10.1016\/j.omton.2025.200952_bib44","doi-asserted-by":"crossref","first-page":"18507","DOI":"10.1073\/pnas.0806213105","article-title":"Inducible and reversible gene silencing by stable integration of an shRNA-encoding lentivirus in transgenic rats","volume":"105","author":"Herold","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omton.2025.200952_bib45","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/S1535-6108(02)00069-7","article-title":"Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412","volume":"1","author":"Weisberg","year":"2002","journal-title":"Cancer Cell"},{"key":"10.1016\/j.omton.2025.200952_bib46","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.38430","article-title":"Thalidomide promotes degradation of SALL4, a transcription factor implicated in Duane Radial Ray syndrome","volume":"7","author":"Donovan","year":"2018","journal-title":"Elife"}],"updated-by":[{"DOI":"10.1016\/j.omton.2025.200966","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T00:00:00Z","timestamp":1750204800000}}],"container-title":["Molecular Therapy Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950329925000219?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950329925000219?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T00:02:25Z","timestamp":1750896145000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950329925000219"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S2950329925000219"],"URL":"https:\/\/doi.org\/10.1016\/j.omton.2025.200952","relation":{},"ISSN":["2950-3299"],"issn-type":[{"value":"2950-3299","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dual CARM1-and IKZF3-targeting: A novel approach to multiple myeloma therapy","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omton.2025.200952","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}],"article-number":"200952"}}